PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma

AIM: A programmed death 1 (PD-1) inhibitor coupled with radiotherapy and antiangiogenic therapy is a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC). We aimed to determine if circulating tumor cells (CTCs) positive for programmed death-ligand 1 (PD-L1) could be employed as...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Ke, Guo, Lu, He, Kun, Rao, Mingyue, Zhang, Jianwen, Yang, Xiaoli, Huang, Weihong, Gu, Tao, Xu, Ke, Liu, Yanlin, Wang, Jing, Chen, Jiali, Wu, Zhenying, Hu, Lanxin, Zeng, Hao, Li, Hongyan, Tong, Jian, Li, Xueting, Yang, Yue, Liu, Hanlin, Xu, Yaoyang, Tan, Zunyuan, Tang, Xue, Feng, Xunjie, Chen, Siyu, Yang, Binbin, Jin, Hongping, Zhu, Lechuan, Li, Bo, Han, Yunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379259/
https://www.ncbi.nlm.nih.gov/pubmed/35982979
http://dx.doi.org/10.3389/fonc.2022.873830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379259/
https://www.ncbi.nlm.nih.gov/pubmed/35982979
http://dx.doi.org/10.3389/fonc.2022.873830

Ejemplares similares